Ming hai Wang
Affiliation: Texas Tech University Health Sciences Center
Suthe S, Yao H, Weng T, Hu C, Feng L, Wu Z, et al
. RON Receptor Tyrosine Kinase as a Therapeutic Target for Eradication of Triple-Negative Breast Cancer: Efficacy of Anti-RON ADC Zt/g4-MMAE. Mol Cancer Ther. 2018;17:2654-2664 pubmed publisher
..Zt/g4-MMAE is highly effective in eradicating TNBC xenografts in preclinical models. These findings lay the foundation for using anti-RON Zt/g4-MMAE in clinical trials as a novel strategy for TNBC treatment. ..
Yao H, Feng L, Suthe S, Chen L, Weng T, Hu C, et al
. Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy. J Immunother Cancer. 2019;7:75 pubmed publisher
..These findings warrant the transition of H-Zt/g4-MMAE into clinical trials in the future. ..
Zeng J, Sharma S, Zhou Y, Yao H, Hu X, Zhang R, et al
. Synergistic activities of MET/RON inhibitor BMS-777607 and mTOR inhibitor AZD8055 to polyploid cells derived from pancreatic cancer and cancer stem cells. Mol Cancer Ther. 2014;13:37-48 pubmed publisher
..Combination of BMS-777607 with AZD8055 achieves the maximal cytotoxic effect on pancreatic cancer and cancer stem cells. ..
Sharma S, Yao H, Zhou Y, Zhou J, Zhang R, Wang M. Prevention of BMS-777607-induced polyploidy/senescence by mTOR inhibitor AZD8055 sensitizes breast cancer cells to cytotoxic chemotherapeutics. Mol Oncol. 2014;8:469-82 pubmed publisher
..Inhibition of mTOR signaling by AZD8055 prevents BMS-777607-induced polyploidy/senescence and increases breast cancer cell chemosensitivity. ..
Feng L, Yao H, Wang W, Zhou Y, Zhou J, Zhang R, et al
. Efficacy of anti-RON antibody Zt/g4-drug maytansinoid conjugation (Anti-RON ADC) as a novel therapeutics for targeted colorectal cancer therapy. Clin Cancer Res. 2014;20:6045-58 pubmed publisher
..Zt/g4-DM1 is highly effective in targeted inhibition of CRC cell-derived tumor growth in mouse xenograft models. This work provides the basis for development of humanized Zt/g4-DM1 for RON-targeted CRC therapy in the future. ..
Feng L, Yao H, Zhou Y, Zhou J, Zhang R, Wang M. Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer. J Exp Clin Cancer Res. 2016;35:70 pubmed publisher
..This work provides the basis for clinical development of humanized Zt/g4-DM1 for potential cancer therapy in the future. ..
Wang M, Lao W, Wang D, Luo Y, Yao H. Blocking tumorigenic activities of colorectal cancer cells by a splicing RON receptor variant defective in the tyrosine kinase domain. Cancer Biol Ther. 2007;6:1121-9 pubmed
..Thus, RONdelta170 is a naturally occurring variant with dominant negative activities and has potential for inhibiting RON-mediated tumorigenic activities in colorectal cancer cells. ..